IDEAYA Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635
IDYA Stock | USD 25.16 0.70 2.71% |
About 79 percent of Ideaya Biosciences' investors are selling. The analysis of the overall investor sentiment regarding Ideaya Biosciences suggests that a fairly large number of traders are terrified. The current market sentiment, together with Ideaya Biosciences' historical and current headlines, can help investors time the market. In addition, many technical investors use Ideaya Biosciences stock news signals to limit their universe of possible portfolio assets.
Ideaya |
IDEAYA Biosciences Inc , a precision medicine oncology company, announced on December 27, 2024, that its Compensation Committee has granted non-qualified
Read at gurufocus.com
Ideaya Biosciences Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Ideaya Biosciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Ideaya Biosciences Fundamental Analysis
We analyze Ideaya Biosciences' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ideaya Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ideaya Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Gross Profit
Gross Profit Comparative Analysis
Ideaya Biosciences is currently under evaluation in gross profit category among its peers. Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Ideaya Biosciences Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Ideaya Biosciences stock to make a market-neutral strategy. Peer analysis of Ideaya Biosciences could also be used in its relative valuation, which is a method of valuing Ideaya Biosciences by comparing valuation metrics with similar companies.
Peers
Ideaya Biosciences Related Equities
VTYX | Ventyx Biosciences | 2.15 | ||||
MLTX | MoonLake Immunotherapeuti | 1.78 | ||||
MGTX | MeiraGTx Holdings | 1.64 | ||||
DAWN | Day One | 0.23 | ||||
RNA | Avidity Biosciences | 0.73 | ||||
SNDX | Syndax Pharmaceuticals | 1.07 | ||||
VRNA | Verona Pharma | 1.13 | ||||
XFOR | X4 Pharmaceuticals | 1.23 | ||||
PTGX | Protagonist Therapeutics | 1.39 | ||||
TERN | Terns Pharmaceuticals | 1.87 | ||||
SWTX | SpringWorks Therapeutics | 2.13 | ||||
KROS | Keros Therapeutics | 2.32 | ||||
RVMD | Revolution Medicines | 2.38 | ||||
INZY | Inozyme Pharma | 4.26 | ||||
AMLX | Amylyx Pharmaceuticals | 4.91 | ||||
ANAB | AnaptysBio | 5.09 | ||||
ABOS | Acumen Pharmaceuticals | 5.82 |
Complementary Tools for Ideaya Stock analysis
When running Ideaya Biosciences' price analysis, check to measure Ideaya Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ideaya Biosciences is operating at the current time. Most of Ideaya Biosciences' value examination focuses on studying past and present price action to predict the probability of Ideaya Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ideaya Biosciences' price. Additionally, you may evaluate how the addition of Ideaya Biosciences to your portfolios can decrease your overall portfolio volatility.
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation |